Bisphosphonates in oncology: Physiopathologic bases and clinical activity

Tumori

Volumn 89, Issue 3, 2003, Pages 223-236

  Riccardi, Alberto ^a   Grasso, Donatella ^a   Danova, Marco ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Bisphosphonates; Breast cancer; Metastatic bone disease; Multiple myeloma; New bisphosphonates; Osteoclastic activation; Prostate cancer; Survival

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RALOXIFENE; TAMOXIFEN; ZOLEDRONIC ACID;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE CANCER; BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DYSPEPSIA; DYSPHAGIA; EARLY CANCER; ESOPHAGUS ULCER; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOKALEMIA; KIDNEY FAILURE; MULTIPLE MYELOMA; MYALGIA; NAUSEA; ONCOLOGY; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT OUTCOME; UVEITIS; VOMITING;

EID: 0042929708     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900301     Document Type: Review

References (169)

1. Riccardi A, Ucci G, Luoni R, Brugnatelli S, Mora O, Spanedda R, De Paoli A, Barbarano L, Di Stasi M, Alberio F, Delfini C, Nicoletti G, Morandi S, Rinaldi E, Piccinini L, Ascari E: Treatment of multiple myeloma according to the extension of the disease: a prospective, randomized study comparing a less with a more aggressive cytostatic policy. Br J Cancer, 70: 1203-1210, 1994.
2. Coleman RE, Smith P, Rubens RD: Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer, 77: 336-340, 1998.
3. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ: Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res, 51: 3059-3061, 1991.
4. Vargas SJ, Gillespie MT, Powell GJ, Southby J, Danks JA, Moseley JM, Martin TJ: Localization of parathyroid hormone-related protein mRNA expression and metastatic lesion by in situ hybridization. J Bone Min Res, 7: 971-980, 1992.
5. Southby J, Kissin MW, Danks JA, Hayman JA, Moseley JM, Henderson MA, Bennett RC, Martin TJ: Immunohistochemical localization of parathyroid hormone-related protein in breast cancer. Cancer Res, 50: 7710-7716, 1990.
6. Downey SE, Hoyland JA, Bundred NJ, Freemont AJ: Parathyroid hormone related protein and its receptor are specifically overexpressed in breast cancer bone metastases. First Int Conf Cancer-Induced Bone Disease, London, June 16-18, p 15, 1997.
7. Brodaus AE, Stewart AF: Malignancy-associated hypercalcemia. In: Endocrinology, 3rd edn, De Groot LJ (Ed), pp 1061-1074, WB Saunders, Philadelphia, 1995.
8. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93: 165-176, 1998.
9. Guise TA: Molecular mechanisms of osteolytic bone metastases. Cancer, 88 (12 suppl): 2892-2898, 2000.
10. Oft M, Heider KH, Beug H: TGF-signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol, 8: 243-252, 1998.
11. Welch DR, Fabra A, Nakajima M: Transforming growth factor stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA, 87: 7678-7682, 1990.
12. Guise TA, Mundy GR: Cancer and bone. Endocr Rev, 19: 18-54, 1998.
13. Suda T, Takahashi N, Udagawa N: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev, 20: 345-357, 1999.
14. Suda T, Udagawa N, Nakamura I, Miyaura C, Takahashi N: Modulation of osteoclast differentiation by local factors. Bone, 17 (2 suppl): 87S-91S, 1995.
15. Van der Pluijm G, Löwik C, Papapoulus S: Tumor progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. Cancer Treat Rev, 26: 11-27, 2000.
16. Cockett MI, Murphy G, Birch ML, O'Connell JP, Crabbe T, Millican AT, Hart IR, Docherty AJ: Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp, 63: 295-313, 1998.
17. Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR: Transforming growth-factor-beta enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer, 75: 721-730, 1998.
18. Unemori EN, Ferrara N, Bauer EA, Amento EP: Vascular endothelial growth factor-induced interstitial collagenase expression in human endothelial cells. J Cell Physiol, 153: 557-562, 1992.
19. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A: Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol, 166: 2023-2031, 2001.
20. Firkin F, Schneider H, Grill V: Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy. Leuk Lymphoma, 29: 499-506, 1998.
21. Roodman GD: Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer, 80 (suppl 8): 1557-1563, 1997.
22. Zeimer H, Firkin F, Grill V, Slavin J, Zhou H, Martin TJ: Assessment of cellular expression of parathyroid hormone-related protein mRNA and protein in multiple myeloma. J Pathol, 192: 336-341, 2000.
23. Lipton A: Bisphosphonates and breast carcinoma. Cancer, 80: 1668-1673, 1997.
24. Body J: Bisphosphonates. Eur J Cancer, 34: 263-269, 1998.
25. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (suppl 12): 2961-2978, 2000.
26. Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Croucher PI, Shipman C, Fleisch HA: The pharmacology of bisphosphonates and new insights into their mechanism of action. J Bone Miner Res, 14 (suppl 2): 56-65, 1999.
27. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res, 13: 581-589, 1998.
28. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ: Bisphosphonates: structure-activity relationships and therapeutic implication. In: Bone and mineral research, Heersche JNM, Kanis JA (Eds), pp 265-306, Elsevier, Amsterdam, 1994.
29. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther, 296: 235-242, 2001.
30. Green JR, Muller K, Laeggi KA: Preclinical pharmacology of GCP 42'446, a new potent, heterocyclic bisphosphonate compound. J Bone Miner Res, 9: 745-751, 1994.
31. Flanagam AM, Chambers TJ: Dichloromethylene-bisphosphonate (CL2MDP) inhibits bone resorption through injury of osteoclasts that resorb CL2MDP-coated bone. Bone Miner, 6: 33-43, 1989.
32. Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL: Two modes of action of bisphosphonates on osteolytic resorption of mineralized bone matrix. Bone Miner, 1: 27-39, 1986.
33. Shipman CM, Croucher PI, Russell RG, Rogers MJ: Bisphosphonate-induced apoptosis in human myeloma cells. First Int Conf Cancer-Induced Bone Disease, London, June 16-18, p 24, 1997.
34. Stutzer A, Fiechsel U, Fleish H: Effects of bisphosphonates on osteoclast number and bone resorption in the rat. J Bone Miner Res, 2: 266-269, 1987.
35. Lowik CW, van der Pluijim G, van der Wee Pals LJ: Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effects of a bisphosphonate. J Bone Miner Res, 3: 185-192, 1988.
36. Fromigue O, Lagneaux L, Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res, 15: 2211-2221, 2000.
37. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer, 84: 1126-1134, 2001.
38. Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Schlagbauer-Wadl H, Berger R: Mechanism of bisphosphonate (alendronate)-induced apoptosis in tumour cells: inhibition of Rhoa activation and disruption of actin cytoskeleton. 5th Workshop on Bisphosphonates, Davos, Switzerland, April 2000. abst 541B18.
39. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res, 57: 3890-3894, 1997.
40. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res, 60: 2949-2954, 2000.
41. Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P: Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res, 16: 2027-2034, 2001.
42. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res, 55: 3551-3557, 1995.
43. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest, 99: 2509-2517, 1997.
44. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, and Rubens RD: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol, 16: 3890-3899, 1998.
45. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med, 339: 357-363, 1998.
46. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol, 20: 3219-3224, 2002.
47. Dallas SL, Garrett IR, Oyajobi BO, Dallas MR, Boyce BF, Bauss F, Radl J, Mundy GR: Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood, 93: 1697-1706, 1999.
48. Shipman CM, Vanderkerken K, Rogers MJ, Lippitt JM, Asosingh K, Hughes DE, Van Camp B, Russell RG, Croucher PI: The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. Br J Haematol, 111: 283-286, 2000.
49. Ezra A, Golomb G: Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev, 42: 175-195, 2000.
50. Adami S, Zamberlan N: Adverse effects of bisphosphonates. A comparative review. Drug Saf, 14: 158-170, 1996.
51. Lin JH: Bisphosphonates: a review of their pharmacokinetic properties. Bone, 18: 75-85, 1996.
52. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol, 19: 558-567, 2001.
53. Coukell AJ, Markham A: Pamidronate: a review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging, 12: 149-168, 1998.
54. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey JA, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J, 7; 377-387, 2001.
55. Tyrrell CT, Bruning PF, May-Levin F, Rose C, Mauriac L, Soukop M, Ford JM: Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer. Eur J Cancer, 31A: 1976-1980, 1995.
56. Vilimovskij A, Thuerlimann JR, Berenson JR, Lira-Puerto VM, Ammon A, Major P, Javier de la Serna Torroba, Seaman JJ: Renal safety and tolerability of 90 mg of Aredia (pamidronate) administered as an intravenous 1 hour infusion: preliminary results (abst 2223). Proc ASCO, 19: 576A, 1999.
57. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst, 94: 1458-1468, 2002.
58. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med, 335: 1785-1791, 1996.
59. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol, 16: 593-602, 1998.
60. Jung A: Comparison of two pareteral diphosphonates in hypercalcemia of malignancy. Am J Med, 72: 221-226, 1982.
61. Urwin GH, Yates AJ, Gray RE, Hamdy NA, McCloskey EV, Preston FE, Greaves M, Neil FE, Kanis JA: Treatment of the hypercalcaemia of malignancy with intravenous clodronate. Bone, 8 (suppl 1): S43-51, 1987.
62. Chapuy MC, Meunier PJ, Alexandre CM, Vignon EP: Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. J Clin Invest, 65: 1243-1247, 1980.
63. Adami S, Mian M: Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Rec Res Cancer Res, 116: 67-72, 1989.
64. Morton AR, Cantrill JA, Craig AE, Howell A, Davies M, Anderson DC: Single dose versus daily intravenous aminohydroxypropylidene bisphosphonate (APD) for the hypercalcemia of malignancy. Br Med J, 296: 811-814, 1988.
65. Body JJ, Pot M, Borkowski A, Sculier JP, Klastersky J: Dose-response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia. Am J Med, 82: 957-963, 1987.
66. Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P: Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol, 6: 762-768, 1988.
67. Cantwell BM, Harris AL: Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcemia caused by cancer. Br Med J, 294: 467-469, 1987.
68. Dodwell DJ, Howell A, Morton AR, Daley-Yates PT, Hoggarth CR: Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumor-induced hypercalcemia. Postgrad Med J, 68: 434-439, 1992.
69. Adami S: Bisphosphonates in prostate carcinoma. Cancer, 80 (suppl 8): 1674-1679, 1997.
70. Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD: Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer, 58: 621-625, 1988.
71. Burckhardt P, Thiebaud D, Perey L, von Fliedner V: Treatment of tumour induced osteolysis by APD. Rec Res Cancer Res, 116: 54-66, 1989.
72. Grabelsky S, Lipton A, Harvey H et al: Pamidronate disodium (APD): a dose seeking study in patients with breast cancer (abst). Proc ASCO, 10: 42, 1991.
73. Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A: Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast cancer. Br Med J, 297: 772-773, 1988.
74. Clarke NW, Holbrook IB, McClure J, George NJ: Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study. Br J Cancer, 63: 420-423, 1991.
75. Rodasavlievic-Asic G, Kacar V, Pavlovic S, Uskokovic Z: Palliative treatment of bone metastases in bronchial carcinoma. First Int Conf Cancer-Induced Bone Disease, London, p 46, June 16-18, 1997.
76. Oura S, Yoshimasu T, Sakurai T, Nakamura T, Kokawa Y, Matsuyama K, Ohta F, Naito Y: Pamidronate therapy for lung cancer patients with bone metastases. Gan To Kagaku Ryoho, 27: 1057-1060, 2000.
77. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Abbruzzese A, Lupoli G: Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer, 84: 1586-1590, 2001.
78. Rosen L, Gordon D, Tchekmedyian S et al: Zoledronic acid significantly increased the median time to first skeletal related event (SRE) in patients with osteolytic bone metastases from non-small cell lung cancer (NSCLC) and other solid tumors (OST). Lung Cancer. 34 (suppl 1): 67, 2001.
79. Van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol, 11: 491-498, 1993.
80. Paterson AH, Powels TJ, Kanis JA, McCloskey E, Hanson J, Ashley S: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol, 11: 59-65, 1993.
81. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol, 16: 2038-2044, 1998.
82. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer, 88: 1082-1090, 2000.
83. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol, 17: 846-854, 1999.
84. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT: Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med, 246: 67-74, 1999.
85. Body JJ, Lichinitser M, Diel I, Schlosser K, Pfarr E, Cavalli F, Dornoff V, Gorbunova VA, McCloskey E, Weiss J, Kanis JA: Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Proc ASCO, 2222A, 1999.
86. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM: Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol, 14: 2552-2559, 1996.
87. Lipton A, Thierault R, Leff R, Gluck S, Stewart J, Costello S, Simeone J, Seaman J, Knigt R, Heffernan M, Reitsma D: Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg pamidronate (Aredia®) infusions. Proc ASCO, 16: 152 (abst 531), 1997.
88. Rizzoli R, Forni M, Schaad MA, Slosman DO, Sappino AP, Garcia J, Bonjour JP: Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone, 18: 531-537, 1996.
89. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New Engl J Med, 334: 488-493, 1996.
90. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol, 100: 317-325, 1998.
91. Belch AR, Bergsagel DE, Wilson K, O'Reilly S, Wilson J, Sutton D, Pater J, Johnston D, Zee B: Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol, 9: 1397-1402, 1991.
92. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, Ford J, Kandra A: Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish cooperative study group. Br J Haematol, 101: 280-286, 1998.
93. Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD: Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol, 20: 2353-2359, 2002.
94. Kylmala T, Taube T, Tammela TL, Risteli L, Risteli J, Elomaa I: Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer, 76: 939-942, 1997.
95. Strang P, Nilsson S, Brandstedt S, Sehlin J, Borghede G, Varenhorst E, Bandman U, Borck L, Englund G, Selin L: The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res, 17: 4717-4721, 1997.
96. Elomaa I, Kylmala T, Tammela T, Viitanen J, Ottelin J, Ruutu M, Jauhiainen K, Ala-Opas M, Roos L, Seppanen J: Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol, 24: 159-166, 1992.
97. Smith JA: Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol, 141: 85-87, 1989.
98. Fernandez-Conde M, Alcover J, Aaron JE, Ordi J, Carretero P: Skeletal response to clodronate in prostate cancer with bone metastases. Am J Clin Oncol, 20: 471-476, 1997.
99. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 91: 1191-1200, 2001.
100. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone, 19: 663-667, 1996.
101. Thurlimann B, Waldburger R, Senn HJ, Thiebaud D: Plicamicyn and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. Ann Oncol, 3: 619-623, 1992.
102. Ralston SH: Medical management of hypercalcaemia. Br J Clin Pharmacol, 34: 11-20, 1992.
103. O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D, Kanis JA: Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer, 67: 560-563, 1993.
104. Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P: Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrPB. J Clin Oncol, 6: 762-768, 1988.
105. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE: A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. Br J Cancer, 72: 1289-1293, 1995.
106. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE: Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol, 15: 131-138, 1997.
107. Dodwell DJ, Abbas SK, Morton AR, Howell A: Parathyroid hormone-related protein and response to pamidronate therapy for tumor-induced hypercalcemia. Eur J Cancer, 27: 1629-1633, 1991.
108. Gurney H, Grill V, Martin TJ: Parathyroid hormone-related protein and response to pamidronate therapy in tumor-induced hypercalcemia. Lancet, 341: 1611-1613, 1993.
109. Body JJ, Louviaux I, Dumon JC: Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Support Care Cancer, 8: 398-404, 2000.
110. Major PP, Coleman RE: Zoledronic acid in the treatment of hypercalcemia of malignancy: results of an international clinical development program. Semin Oncol, 28 (suppl 6): 17-24, 2001.
111. Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghe F, Pannuti F: Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology, 48: 97-101, 1991.
112. Robertson AG, Reed NS, Ralston SH: Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol, 13: 2427-2430, 1995.
113. O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA: Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol, 13: 929-934, 1995.
114. Ernst DS, MacDonald RN, Paterson AH, Jensen J, Brasher P, Bruera E: A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symp Manag, 7: 4-11, 1992.
115. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet, 340: 1049-1052, 1992.
116. Body JJ, Coleman RE, Piccart M: Use of bisphosphonates in cancer patients. Cancer Treat Rev, 22: 265-287, 1996.
117. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol, 16: 3890-3899, 1998.
118. Coleman RE, Purohit OP, Vinholes JJ, Zekri J: High dose pamidronate: Clinical and biochemical effects in metastatic bone disease. Cancer, 80 (suppl 8): 1686-1690, 1997.
119. Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E: A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symp Manag, 13: 319-326, 1997.
120. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Engl J Med, 335: 1785-1791, 1996.
121. Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: A dose seeking study. Cancer, 74: 2949-2955, 1994.
122. Koeberle D, Bacchus L, Thuerlimann B, Senn HJ: Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Support Care Cancer, 7: 21-27, 1999.
123. Groff L, Zecca E, De Conno F, Brunelli C, Boffi R, Panzeri C, Cazzaniga M, Ripamonti C: The role of disodiom pamidronate in the management of bone pain due to malignancy. Palliative Med, 15: 297-307, 2001.
124. Merlini G, Parrinello GA, Piccinini L, Crema F, Fiorentini ML, Riccardi A, Pavesi F, Novazzi F, Silingardi V, Ascari E: Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol, 8: 23-30, 1990.
125. Pelger RC, Hamdy NA, Zwinderman AH, Lycklama a Nijeholt AA, Papapoulos SE: Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone, 22: 403-408, 1998.
126. Rodasavlievic-Asic G, Kacar V, Pavlovic S, Uskokovic Z: Palliative treatment of bone metastases in bronchial carcinoma. First Int Conf Cancer-Induced Bone Disease, London, June 16-18, 1997, abst 41, 1997.
127. Piga A, Bracci R, Ferretti B, Sandri P, Nortilli R, Acito L, Pancotti A, Di Furia L, Carle F, Cellerino R: A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res, 17: 213-217, 1998.
128. Chow E, Danjoux C, Wong R, Szumacher E, Franssen E, Fung K, Finkelstein J, Andersson L, Connolly R: Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Radiother Oncol, 56: 305-314, 2000.
129. Macro M, Bouvard G, Le Gangneux E, Colin T, Loyau G: Intravenous aminohydroxypropylidene bisphosphonate does not modify 99mTc-hydroxymethylene bisphosphonate bone scintigraphy. A prospective study. Rev Rhum Engl Ed, 62: 99-104, 1995.
130. Pecherstorfer M, Schilling T, Janisch S, Woloszczuk W, Baumgartner G, Ziegler R, Ogris E: Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med, 34: 1039-1044, 1993.
131. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res, 60: 2949-2954, 2000.
132. Fleisch H: Bisphosphonates: mechanisms of action. Endocr Rev 19: 80-100, 1998.
133. Berenson JR, Lipton A: Bisphosphonates in the treatment of malignant bone disease. Ann Rev Med, 50: 237-248, 1999.
134. Body JJ, Lichinitser M, Diel I, Schlosser K, Pfarr E, Cavalli F, Dornoff V, Gorbunova VA, McCloskey E, Weiss J, Kanis JA: Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Proc ASCO, 18: 575, 2222A, 1999.
135. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG: American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology Guidelines on the role of bisphosphonates in breast cancer. J Clin Oncol, 18: 1378-1391, 2000.
136. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann S: American Society of Clinical Oncology Bisphosphonates Expert Panel. Practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol, 20; 3719-3736, 2002.
137. Saarto T, Blomqvist C, Virkkunen P, Elomaa I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol, 19: 10-17, 2001.
138. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J, Pylkkanen L: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol, 20: 3219-3224, 2002.
139. Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmstrom T: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet, 1: 146-149, 1983.
140. Elomaa I, Blomqvist C, Porkka L, Holmstrom T, Taube T, Lamberg-Allardt C, Borgstrom GH: Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother, 42: 111-116, 1988.
141. Diel IJ, Solomayer EF, Gollan C, Schtz F, Bastert G: Bisphosphonates in the reduction of metastases in breast cancer. Results of the extended follow-up of the first study population. Proc ASCO, 314A, 2000.
142. Riccardi A, Ucci G, Brugnatelli S, Mora O, Merlini GP, Piva N, De Paoli A, Barbarano L, Di Stasi M, Alberio F, Nicoletti G, Morandi S, Rinaldi E, Piccinini L, Ascari E (for the Cooperative Group of Study and Treatment of Multiple Myeloma): A prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma. Int J Oncol, 5: 833-839, 1994.
143. Delmas PD, Fontana A: Bone loss induced by cancer treatment and its management. Eur J Cancer, 34: 260-262, 1998.
144. Friedlaender GE, Tross RB, Doganis AC, Kirkwood JM, Baron R: Effects of chemotherapeutic agents on bone. J Bone Joint Surg, 66A: 602-610, 1984.
145. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY: Effects on bone mass of long-term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Met, 81: 4278-4289, 1996.
146. Holmes SJ, Whitehouse RW, Clark ST, Crowther DC, Adams JE, Shalet SM: Reduced bone mineral density in men following chemotherapy for Hodgkin's disease. Br J Cancer, 70: 371-375, 1994.
147. Redman JR, Bajorunas DR, Wong G, McDermott K, Gnecco C, Schneider R, Lacher MJ, Lane JM: Bone mineralization in women following treatment for Hodgkin's disease. Am J Med, 85: 65-72, 1988.
148. Mincey BA, Moraghan TJ, Perez EA: Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clinic Proc, 75: 821-829, 2000.
149. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in
150. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG: American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol, 17: 1939-1955, 1999.
151. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 90: 1371-1388, 1998.
152. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Engl J Med, 337: 1641-1647, 1997.
153. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Ferguson L, Chen V, Lee K, Greenspan SL: Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab, 83: 2324-2330, 1998.
154. Powles TJ, McCloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A, Rosenqvist, K, Kanis J: Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst, 90: 704-708, 1998.
155. Delmas PB, Balena R, Confavreux E, Hardouin C, Hardy P, Bremond A: Bishosphonate risendronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind placebo-controlled study. J Clin Oncol, 15: 955-962, 1997.
156. Köberle D, Bacchus L, Thuerlimann B, Senn HJ: Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Support Care Cancer, 7: 21-27, 1999.
157. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, Harris ST, Santora AC 2nd, Hirsch LJ, Oppenheimer L, Thompson D: Prevention of non vertebral fractures by alendronate. JAMA, 277: 1159-1164, 1997.
158. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet, 348: 1535-1541, 1996.
159. Vinholes J, Coleman R, Lacombe D, Rose C, Tubiana-Hulin M, Bastit P, Wildiers J, Michel J, Leonard R, Nortier J, Mignolet F, Ford J: Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer, 80: 221-228, 1999.
160. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, Theriault R, Clemens D, Costa L, Seaman J, Knight R: Markers of bone resorption in patients treated with pamidronate. Eur J Cancer, 34: 2021-2026, 1998.
161. Engler H, Koeberle D, Thuerlimann B, Senn HJ, Riesen WF: Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clin Chem Lab Med, 36: 879-885, 1998.
162. Vinholes J, Coleman R, Eastell R: Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev, 22: 289-331, 1996.
163. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, Theriault R, Clemens D, Costa L, Seaman J, Knight R: Markers of bone resorption in patients treated with pamidronate. Eur J Cancer, 34: 2021-2026, 1998.
164. Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A: A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer, 91: 144-154, 2001.
165. Kylmala T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I: Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer, 29A: 821-825, 1993.
166. Neri B, Gemelli MT, Sambataro S, Colombi L, Benvenuti F, Ludovici M, Pacini P: Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases. Anticancer Drugs, 3: 87-90, 1992.
167. Nussbaum SR, Warrell RP Jr, Rude R, Glusman J, Bilezikian JP, Stewart AF, Stepanavage M, Sacco JF, Averbuch SD, Gertz BJ: Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol, 11: 1618-1623, 1993.
168. Ralston SH, Thiebaud D, Herrmann Z, Steinhauer EU, Thurlimann B, Walls J, Lichinitser MR, Rizzoll R, Hagberg H, Huss HJ, Tubiana-Hulin M, Body JJ: Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia. Br J Cancer, 75: 295-300, 1997.
169. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thurlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiebaud D: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol, 14: 268-276, 1996.